|Articles|May 21, 2012
FDA's $6.4 Billion Plan for Quick Reviews Moves to Senate
Advertisement
Mylan Inc.
(MYL)
Pfizer Inc. (PFE)
A $6.4 billion effort to speed U.S. reviews of new drugs and medical devices is a step closer to law as the agreements , and other companies struck with regulators wind through Congress.
The Senate is set to begin voting as soon as today on more than $2 billion in new fees that drug and device companies will pay regulators through 2017 to review products for safety and efficacy. The figure includes $1.56 billion from generic-drug companies such as Canonsburg, Pennsylvania-based Mylan, which had been exempt from such fees.
Read the full story:
Source: Bloomberg
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
2
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
3
FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies
4
A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD
5